The Pro12→Ala Substitution in PPAR-γ Is Associated With Resistance to Development of Diabetes in the General Population-Reference-Cited by-同舟云学术

The Pro12→Ala Substitution in PPAR-γ Is Associated With Resistance to Development of Diabetes in the General Population

Published:2001-04-01 Issue:4 Volume:50 Page:891-894
ISSN:0012-1797
Container-title:Diabetes
language:en
Short-container-title:

Author:

Mori Hiroyuki¹,Ikegami Hiroshi²,Kawaguchi Yoshihiko²,Seino Susumu³,Yokoi Norihide³,Takeda Jun⁴,Inoue Ituro⁴,Seino Yutaka⁵,Yasuda Koichiro⁵,Hanafusa Toshiaki⁶,Yamagata Kazuya⁶,Awata Takuya⁷,Kadowaki Takashi⁸,Hara Kazuo⁸,Yamada Nobuhiro⁹,Gotoda Takanari¹⁰,Iwasaki Naoko¹¹,Iwamoto Yasuhiko¹¹,Sanke Tokio¹²,Nanjo Kishio¹³,Oka Yoshitomo¹⁴,Matsutani Akira¹⁴,Maeda Eiichi¹,Kasuga Masato¹

Affiliation:

1. Second Department of Internal Medicine, Kobe University School of Medicine, Kobe

2. Department of Geriatric Medicine, Osaka University Medical School, Osaka

3. Department of Molecular Medicine, Chiba University Graduate School of Medicine, Chiba

4. Laboratory of Molecular Genetics, Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma

5. Department of Metabolism and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto

6. Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka

7. Fourth Department of Medicine, Saitama Medical School, Saitama

8. Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo

9. Institute of Clinical Medicine Metabolism, Endocrinology, and Atherosclerosis, University of Tsukuba, Tsukuba, Ibaraki

10. Department of Metabolic Diseases, Faculty of Medicine, University of Tokyo

11. Diabetes Center, Tokyo Women’s Medical University, Tokyo

12. Department of Clinical Laboratory Medicine and the

13. First Department of Medicine, Wakayama University of Medical Science, Wakayama

14. Third Department of Internal Medicine, Yamaguchi University, School of Medicine, Yamaguchi, Japan

Abstract

The allele frequencies for a Pro12→Ala substitution in peroxisome proliferator–activated receptor-γ differ among ethnic groups, and its relationship with diabetes and associated diseases is controversial. The prevalence of this polymorphism and its effects on clinical characteristics have now been evaluated with a large number of Japanese individuals with type 2 diabetes (n = 2,201) and normal control subjects (n = 1,212) recruited by 10 institutions located in seven different cities in Japan. The allele frequency for the Ala12 variant was significantly lower in the type 2 diabetic group than in the control group (2.39 vs. 4.13%, P = 0.000054). However, compared with subjects without the Ala12 variant, the diabetic subjects with this variant exhibited a significantly higher serum concentration of total cholesterol (P = 0.001), manifested a reduced capacity for insulin secretion as evaluated by homeostasis model assessment (P = 0.007), and tended to possess a higher level of HbA1c. These data suggest that the Ala12 variant is associated with a reduced risk for the development of diabetes in the general population, but that it may be also a risk factor for insulin deficiency and disease severity in individuals with type 2 diabetes.

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://journals.org/diabetes/diabetes/article-pdf/50/4/891/368419/891.pdf

Reference16 articles.

1. Barroso L, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O’Rahilly S: Dominant negative mutation in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883, 1999

2. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARγ 2 missense mutation. Biochem Biophys Res Commun 241:270–274, 1997

3. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287, 1998

4. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212–216, 2000

5. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80, 2000

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence Linking PPARG Genetic Variants with Periodontitis and Type 2 Diabetes Mellitus in a Brazilian Population;International Journal of Molecular Sciences;2023-04-05

2. Decoding type 2 diabetes mellitus genetic risk variants in Pakistani Pashtun ethnic population using the nascent whole exome sequencing and MassARRAY genotyping: A case-control association study;PLOS ONE;2023-01-27

3. Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients;Journal of Diabetes & Metabolic Disorders;2022-12-22

4. G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis;Frontiers in Endocrinology;2022-06-29

5. Ethnic disparities attributed to the manifestation in and response to type 2 diabetes: insights from metabolomics;Metabolomics;2022-06-28